The latest research from Fore Pharma, Spain Schizophrenia Market and Competitive Landscape Highlights – 2016, provides comprehensive insights into Schizophrenia pipeline products, Schizophrenia epidemiology, Schizophrenia market valuations and forecast, Schizophrenia products sales and competitive landscape in Spain.
The research is classified into nine sections – Schizophrenia overview including etiology, pathophysiology, and diagnosis, Schizophrenia treatment options, Schizophrenia pipeline products, Schizophrenia market analysis comprising of Schizophrenia epidemiology, key products marketed for Schizophrenia, market valuations and forecast, products sales and market shares.
Research Scope: - Schizophrenia Pipeline: Find out the products in clinical trials for the treatment of Schizophrenia by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products - Schizophrenia Epidemiology: Find out the number of patients diagnosed (prevalence) with Schizophrenia in Spain - Schizophrenia Products: Identify key products marketed and prescribed for Schizophrenia in Spain, including trade name, molecule name, and company - Schizophrenia Product Sales: Find out the sales revenues of Schizophrenia products, both branded and generics, in Spain - Schizophrenia Market Valuations: Find out the market size for Schizophrenia products in 2015 in Spain. Find out how the market advanced from 2010 and forecast to 2020 - Schizophrenia Products Market Share: Find out the market shares for key Schizophrenia products in Spain
Benefits of this Research: The research helps executives to - Support monitoring and reporting national Schizophrenia market analysis and sales trends - Track competitor drugs sales and market share in Spain Schizophrenia market - Track competitive developments in Schizophrenia market and present key issues and learnings - Synthesize insights for Schizophrenia market and products to drive business performance - Answer key business questions about the Schizophrenia market - Evaluate commercial market opportunity assessment, positioning, and segmentation for Schizophrenia products - Supports decision making in R&D to long term marketing strategies
Our reports have been used by over 10K customers, including:
‘Gene and Cell Therapies targeting CNS Disorders – Market Insights and Market Forecast – 2026’ report delivers an in-depth understanding of the market trends of Gene and Cell Therapies targeting CNS Disorders in in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Gene and Cell Therapies targeting...
116 pages •
By Asia Market Information & Development Company
• Sep 2020
This study focuses on China’s Central Nervous System Disorder Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one...
Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2020
According to the recently published report ’Metabotropic Glutamate Receptor 5 – Pipeline Review, H1 2020’; Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 19 molecules. Out of...
Metabotropic Glutamate Receptor 2 - Pipeline Review, H1 2020
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes....
Road to recovery: Growing demand for and acceptance of industry services will boost revenue Abstract Mental Health & Substance Abuse Centres in Canada The rising awareness and acceptance of mental health and substance abuse illnesses have contributed to revenue growth for the Mental Health and Substance...
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2018 Summary Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation...
Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Autism Spectrum Disorders in 22 Major Markets Autism Spectrum Disorders (ASD) or Pervasive Developmental Disorder (PDD) defines a group of developmental disability disorders. These disorders include: Autism, Pervasive Developmental Disorder not otherwise specified (PDD-NOS), Asperger...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.